ARTICLES LIST

Clear Search

Select the Article Source National Cancer Institute Office of Dietary Supplements National Institute on Aging Healthfinder.gov National Institute of Child Health and Human Development Centers for Disease Control and Prevention Administration for Children and Families National Institute of Environmental Health Sciences National Library of Medicine National Institute of Allergy and Infectious Diseases National Center for Complementary and Integrative Health National Institute of Neurological Disorders and Stroke NIH Senior Health National Institute of Arthritis and Musculoskeletal and Skin Diseases Health and Human Services National Institute of General Medical Sciences National Institute of Dental and Craniofacial Research National Human Genome Research Institute Food and Drug Administration Center for Tobacco Products Public Health and Medical Emergency Support for a Nation Prepared Office of Disease Prevention and Health Promotion, Healthy People National Institute on Drug Abuse National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases U S Food and Drug Administration National Institute on Deafness and Other Communication Disorders National Heart, Lung, and Blood Institute

Media ID	Source Name	Media Type	Language	Media Name	Media Description	Keywords	Keywords	Link to Article
1383	National Cancer Institute	Html	en	Primary CNS Lymphoma Treatment (PDQ®)–Health Professional Version	Expert-reviewed information summary about the treatment of primary CNS lymphoma.	neurologic toxic effects 0.298255 phase II study 0.301181 Median survival times 0.290496 autologous stem-cell transplantation 0.303999 intraocular lymphoma 0.357403 Int J Radiat 0.280843 multicenter trial 0.337891 high-dose chemotherapy 0.457349 Radiat Oncol Biol 0.35284 newly diagnosed patients 0.281995 median overall survival 0.288155 median OS 0.305882 oncology group study 0.287293 Median progression-free survival 0.289876 patients 0.38833 hematopoietic stem-cell rescue 0.299776 intensive chemotherapy 0.334942 refractory CNS lymphoma 0.401669 recurrent primary CNS 0.355753 Enhanced Chemotherapy Delivery 0.290362 immunodeficiency syndrome-related lymphoma 0.3182 radiation therapy 0.416652 radiotherapy 0.304692 high-dose cytarabine 0.339318	Ferreri AJ 0.299732 et al. 0.375948 brief single-agent methotrexate 0.293099 Non-AIDS Primary CNS 0.32387 intrathecal methotrexate 0.298746 PUBMED Abstract 0.333438 median time-to-treatment failure 0.282021 primary cns lymphoma 0.672691 median follow-up 0.314518 intraventricular methotrexate 0.280851 autologous stem cell 0.35468 radiation therapy oncology 0.371114 Abstract 0.508209 Clin Oncol 0.757019 Oncol Biol Phys 0.354909 high-dose methotrexate-based chemotherapy 0.379055 primary brain lymphoma 0.340924 Lymphoma Group Phase 0.33918 high-dose methotrexate-based therapy 0.321219 nervous system lymphoma 0.614476 primary cns 0.932952 therapy oncology group 0.373019 DeAngelis LM 0.317758 high-dose methotrexate 0.643572	CLICK HERE
1457	National Cancer Institute	Html	en	Esophageal Cancer Prevention (PDQ®)–Patient Version	Expert-reviewed information summary about factors that may influence the risk of developing esophageal cancer and about research aimed at the prevention of this disease.	cancer treatment 0.286725 cancer prevention trials 0.390926 protective factors 0.401778 following PDQ summaries 0.346585 PDQ cancer information 0.534006 Clinical Trials section 0.298655 esophageal cancer prevention 0.457641 clinical trials 0.60082 kidney damage 0.286456 cancer information summary 0.441092 lower esophagus 0.410035 lower sphincter muscle 0.357661 breast cancer prevention 0.318294 patients 0.3021 cancer patients 0.287439 latest published information 0.293022 cancer risk factor 0.360882 NCI’s PDQ 0.303811 NCI PDQ cancer 0.377375 stomach acid 0.297556 radiofrequency ablation 0.407628 PDQ Screening 0.291859 abnormal cells 0.372908 cancer risk factors 0.361881	Cancer prevention 0.541167 esophageal cancer 0.615396 cancer protective factor 0.339428 esophageal cancer increases 0.350762 Barrett esophagus 0.51844 Cancer Information Service 0.327169 prevention clinical trials 0.346293 Prevention Editorial Board 0.348856 treatment clinical trials 0.298225 National Cancer Institute 0.429589 Nonsteroidal anti-inflammatory drugs 0.365737 PDQ documents 0.293539 new treatment 0.29433 Cancer Care page 0.315656 PDQ database 0.297589 adenocarcinoma 0.336667 PDQ summary 0.318797 cancer clinical trials 0.340291 risk factors 0.504317 cancer information summaries 0.334653 comprehensive cancer information 0.334858 cancer 0.918802 esophagus produce 0.402126 esophagus 0.723728	CLICK HERE
1477	National Cancer Institute	Html	en	Bladder Cancer Treatment (PDQ®)–Health Professional Version	Expert-reviewed information summary about the treatment of bladder cancer.	Ta T1 bladder 0.556554 T1 high-grade bladder 0.506904 superficial bladder tumour 0.53364 bacillus calmette-guerin 0.516715 transitional cell carcinoma 0.695076 T1 transitional cell 0.496806 bladder cancer 0.986423 der Meijden AP 0.500317 clinical trials 0.520234 intravesical bacillus Calmette-Guerin 0.513656 primary superficial bladder 0.615094 non-muscle invasive bladder 0.495804 T1 bladder cancer 0.609466 Malignant bladder tumors 0.513021 superficial bladder cancer 0.787159 bladder tumors 0.61916 van der Meijden 0.529014 patients 0.562152 advanced bladder cancer 0.510311 Invasive T1 bladder 0.497584 high-grade T1 bladder 0.499638 newly diagnosed bladder 0.507837 superficial bladder tumors 0.5725 bacillus calmette-guerin therapy 0.514624	metastatic bladder cancer 0.563646 Canadian Bladder Cancer 0.508472 et al. 0.600299 bladder carcinogenesis 0.499935 high-grade bladder cancer 0.517381 bladder cancer. 0.49995 Eur Urol 0.553395 PUBMED Abstract 0.561063 invasive bladder cancer 0.614868 radical cystectomy 0.523916 non-muscle-invasive bladder cancer 0.573969 transurethral resection 0.509808 bladder cancer coincides 0.50967 advanced bladder carcinoma 0.508345 Abstract 0.681067 Herr HW 0.527009 Clin Oncol 0.566437 bladder carcinoma 0.546923 Urol 0.572506 urothelial carcinoma 0.574639 invasive bladder carcinoma 0.507022 nonmuscle-invasive bladder cancer 0.533359 Low-grade bladder cancers 0.509091 bladder cancer health 0.52478	CLICK HERE
1652	National Cancer Institute	Html	en	PC-SPES (PDQ®)–Patient Version	Expert-reviewed information summary about the use of PC-SPES as a treatment for prostate cancer. Note: The information in this summary is no longer being updated and is provided for reference purposes only.	cancer treatment 0.437115 cancer prevention 0.282542 Complementary Therapies Editorial 0.411772 United States 0.349637 Drug Administration 0.423619 Cancer Information Specialist 0.306354 PC-SPES 0.776503 Cancer Information Service 0.45748 PDQ cancer information 0.587454 Cancer Complementary 0.346119 CAM therapies 0.322693 treatment clinical trials 0.274541 National Cancer Institute 0.691988 clinical trials 0.701375 alternative medicine 0.539683 PC-SPES lowers PSA 0.309751 U.S. Food 0.291013 conventional treatment 0.269047 health care 0.271323 cancer information summary 0.466619 alternative cancer therapies 0.329832 Federal Trade Commission 0.302224 National Institutes 0.284819 cancer cells 0.400978	clinical trial 0.31949 National Center 0.264606 prostate cancer cells 0.342551 CAM cancer research 0.300048 breast cancer prevention 0.277639 cancer patients 0.279371 Cancer Care page 0.279808 prostate specific antigen 0.386617 traditional Chinese medicine 0.370287 health 0.346702 NCI’s PDQ 0.273024 PDQ summary 0.278148 Integrative Health 0.265541 NCI PDQ cancer 0.391945 cancer information database 0.323738 prostate cancer 0.519752 effects 0.26747 prescription medicines 0.565306 alternative therapies 0.390035 cancer information summaries 0.324417 Therapies Editorial Board 0.356431 cancer 0.944963 prostate problems 0.265671	CLICK HERE
1705	National Cancer Institute	Html	en	Cancer Vaccines	A fact sheet discussing how cancer vaccines are used to harness the body’s immune system to protect against cancer-causing viruses and as immunotherapy to treat existing cancers.	vaccines target 0.540823 Anti-cancer vaccines 0.524975 abnormal cells 0.538771 antitumor immune response 0.513051 cancer vaccines 0.904526 specific immune responses 0.519605 traditional vaccines 0.550486 cancer cells 0.789704 allogeneic vaccines 0.526888 human papillomavirus vaccines 0.559079 multiple vaccines 0.540847 immune responses 0.691208 killer T cells 0.622141 M. Cancer vaccines 0.584037 cancer-associated antigens 0.612713 dendritic cells 0.519133 white blood cells 0.606559 immune response 0.721657 cancer treatment vaccine 0.564337 dendritic cell vaccines 0.544937 immune checkpoint 0.531831 clinical trials 0.608279 anticancer vaccines 0.541706 anticancer immune response 0.511669	tumor cells 0.510012 anticancer immune responses 0.598324 effective treatment vaccines 0.575167 normal cells 0.555313 metastatic prostate cancer 0.537182 cancer treatment vaccines 0.999587 anti-idiotype vaccines 0.527061 prostate cancer cells 0.562932 immune cells 0.566337 cancer preventive vaccines 0.728942 cancer antigens 0.523547 tumor cell vaccines 0.548556 Forni G. Vaccines 0.537061 cells 0.810385 cytotoxic t cells 0.520347 Clinical Cancer Research 0.524363 strong immune response 0.509393 et al 0.519859 immune system cells 0.584226 cancer preventive vaccine 0.510434 current vaccines 0.524179 therapeutic cancer vaccines 0.612595 natural immune response 0.518594	CLICK HERE
1713	National Cancer Institute	Html	en	Mammograms	A fact sheet that defines screening and diagnostic mammograms; discusses the benefits and potential harms of screening mammograms; and summarizes how findings, including breast density, are reported.	mammography facility 0.617711 randomized breast screening 0.57821 mammograms 0.675286 tomosynthesis mammography 0.551922 3-D mammography 0.578436 health care provider 0.558006 breast implants 0.579825 clinical breast exams 0.637306 low-cost screening mammogram 0.569796 FDA-certified mammography facilities 0.561341 breast cancers 0.551598 dense breasts 0.550925 mammography screening programs 0.6099 diagnostic mammography 0.569303 conventional mammography 0.61609 standard digital mammography 0.569915 diagnostic mammogram 0.562845 high breast density 0.542253 mammography screening 0.620292 breast tissue 0.554504 Breast Imaging Reporting 0.535488 local mammography facility 0.561875 Regular breast self-exam 0.536763 mammogram 0.686942	breast cancer screening. 0.555392 digital mammography 0.659536 breast size 0.53014 regular screening mammography 0.636566 Mammography Quality Standards 0.561193 diagnostic mammograms 0.537673 digital breast tomosynthesis 0.539944 breast pain 0.528266 False-positive mammogram results 0.54885 mammography facilities 0.595109 breast cancer screening 0.594468 mammography 0.783904 breast density 0.567834 breast cancer 0.951318 annual screening mammograms 0.562698 standard mammography 0.551771 2-D mammography 0.551301 high-quality screening mammograms 0.56602 Mammography Imaging Screening 0.608506 previous breast biopsies 0.545681 screening mammogram 0.619625 false-negative results 0.544234 mammography providers 0.542876	CLICK HERE
1807	National Cancer Institute	Html	es	Tratamiento de la leucemia linfoblástica aguda infantil (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca del tratamiento de la leucemia linfoblástica aguda infantil.	Natl Acad Sci 0.307376 Pediatric Oncology 0.305639 cuadro clínico 0.310887 accessed august 0.319526 Cancer Statistics Review 0.318661 Sin embargo 0.315253 American Cancer Society 0.312133 células t 0.309906 acute lymphoblastic leukaemia 0.410489 childhood acute lymphoblastic 0.499677 Nat Rev Cancer 0.306219 Declining childhood 0.306804 Estados Unidos 0.313559 Natl Cancer Inst 0.305713 Howlader N 0.306702 cord blood from 0.305809 Nat Genet 0.357137 Childhood Oncology Group 0.313596 Smith MA 0.306166 SEER Cancer Statistics 0.320166 Lancet Oncol 0.309044 compromiso testicular manifiesto 0.308702 gen mll 0.318674 influences childhood 0.306473 leucemia aguda 0.314027	reordenamientos mll 0.307367 Lymphoblastic Leukemia Based 0.308731 Proc Natl Acad 0.307623 leucemia linfoblástica aguda 0.338126 Noone AM 0.306815 Pediatr Blood Cancer 0.327193 acute lymphocytic leukemia 0.309611 childhood leukaemia 0.319593 Chessells JM 0.307957 National Cancer Institute 0.329181 Genes Chromosomes Cancer 0.305628 with down 0.333227 childhood leukemia 0.309509 Hosking FJ 0.306858 Acute leukaemia 0.30596 sistema nervioso central 0.310053 Dutch Childhood Oncology 0.31389 childhood b-cell 0.31228 Krapcho M 0.307706 acute lymphoblastic leukemia 0.986055 leucemia mieloide aguda 0.30545 Mullighan CG 0.306442 minimal residual disease 0.306428 células b 0.314985	CLICK HERE
1947	National Cancer Institute	Html	es	Tratamiento del cáncer de laringe (PDQ®)–Versión para pacientes	Resumen de información revisada por expertos acerca del tratamiento del cáncer de laringe.	glándula tiroides 0.639428 Hemilaringectomía cirugía 0.60821 Neck Cancer 0.605848 siguientes procedimientos 0.707332 laringectomía parcial ayuda 0.615346 estadio ii 0.651257 rayos x 0.611158 pequeñas marcas 0.606254 estadio ivb 0.616957 estadio ivc 0.633063 enlace drugs approved 0.610885 tratado.ampliar radioterapia 0.630743 órgano fonador 0.612088	National Cancer Institute 0.602872 siguientes riesgos 0.602157 malla ayuda 0.606514 Instituto Nacional 0.606325 PDQ Tratamiento 0.606553 presente sección 0.60533 Physician Data Query 0.613617 haz angosto 0.606683 ganglio linfático mide 0.979756 laringe dónde 0.67158 paciente respire 0.60867 siguientes estadios 0.629924	CLICK HERE
15644	National Cancer Institute	Html	en	Grant Resources	Resources to help with the NCI and NIH grants and funding process.	common grants terms 0.636173 Grants Administration 0.485213 application receipt dates 0.392845 grants lifecycle 0.493875 advisory boards 0.274696 peer review process 0.434219 Grant PDF 0.319331 special initiatives 0.261878 Federal Register 0.286844 legal notices 0.272989 official daily publication 0.406084 general description 0.295596 broad overview 0.295794 final regulations 0.265095 nih grants 0.999484 White House Office 0.40002 Funding Language 0.367422 grant process 0.330736 government-wide compendium 0.296699 award schedules 0.255197 Scientific Review 0.263296	NIH grants processing 0.800737 NIH electronic Research 0.624902 free NCI publications 0.595046 federal agencies 0.408435 local governments 0.266683 grants management contacts 0.622121 NIH-funded research projects 0.396147 NCI extramural funding 0.747162 NCI Division 0.471899 Extramural Activities 0.341398 nonprofit institutions 0.268579 NCI Office 0.478785 open funding opportunities 0.500892 ) Commons 0.273665 official resource 0.262995 NIH Publications 0.474143 financial assistance programs 0.412746 federal programs 0.291934 on-going administration requirements 0.443665 publications patents 0.270405 Federal Domestic Assistance 0.437119	CLICK HERE
16652	National Cancer Institute	Html	en	Track 2: Oncology Product Research and Review for B.C. Oncologists	NCI and FDA collaborate to train physicians in aspects of drug, biologic, or device development and standards for assessing medical product safety. Learn more about this cancer training program.	regulatory research 0.59502 pre-screened pool 0.579358 related issues 0.586202 reviewer training 0.576269 FDA scientific review 0.753981 later potential exposure 0.734497 regulatory meetings 0.582894 permanent residency 0.578922 Medical Center Dr 0.681374 fellows 0.986099 application guidelines 0.556272 clinical trials 0.592135 translational research 0.577443 various courses 0.556327 grand rounds 0.56318 various regulatory activities 0.729982 Regulatory Review Fellowships 0.720449 Cancer Training 0.567352 branch chief 0.561743 clinical divisions 0.572535 FDA Centers 0.764003 Review list 0.568699 training program 0.574879 application materials 0.560557 relevant federal statutes 0.739941	formal training 0.600328 U.S. citizenship 0.583794 earliest start date 0.680448 particular product 0.577316 office meetings 0.559685 senior member 0.553306 regulatory presentations 0.582975 guidance document development 0.691126 designee 0.446918 basic bench science 0.743323 principal investigators 0.569533 medical product safety 0.755593 Office Phone 0.552001 NCI-FDA Research 0.556736 one-year program 0.583619 supplemental training 0.588935 division director 0.57667 efficacy 0.476236 limited human exposure 0.741021 FDA medical review 0.830025 device development 0.579671 broader patient population 0.734715 clinical reviews 0.569332 pharmacology/toxicology 0.443629	CLICK HERE